Dicerna Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. Dicerna’s entire drug pipeline is generated from its proprietary RNA interference (RNAi) technology platform, which is believed to improve upon existing RNAi technologies. RNAi is a highly potent and specific mechanism for silencing the activity of a targeted disease-driving gene. Dicerna’s discovery approach is based on proprietary double-stranded RNA molecules which the Company believes maximizes RNAi potency.

Employee Rating

2.3More
TypePublic
HQCambridge, US
Founded2007
Size (employees)44 (est)-6%
Websitedicerna.com
Dicerna Pharmaceuticals was founded in 2007 and is headquartered in Cambridge, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Dicerna Pharmaceuticals

Douglas M. Fambrough

Douglas M. Fambrough

President and Chief Executive Officer
Bob D. Brown

Bob D. Brown

Chief Scientific Officer, Senior Vice President
Jack Green

Jack Green

CFO
Jennifer Lockridge

Jennifer Lockridge

Senior Vice President, Program Development
David Miller

David Miller

Senior Vice President, Corporate Operations
Ralf Rosskamp

Ralf Rosskamp

Chief Medical Officer
Show more

Dicerna Pharmaceuticals Office Locations

Dicerna Pharmaceuticals has an office in Cambridge
Cambridge, US (HQ)
87 Cambridge Park Dr
Show all (1)
Report incorrect company information

Dicerna Pharmaceuticals Financials and Metrics

Dicerna Pharmaceuticals Revenue

Dicerna Pharmaceuticals's revenue was reported to be $1.18 m in FY, 2017
USD

Net income (Q2, 2018)

(35.6m)

EBIT (Q2, 2018)

(35.8m)

Market capitalization (17-Jan-2019)

700.1m

Closing stock price (17-Jan-2019)

11.2

Cash (30-Jun-2018)

42.4m
Dicerna Pharmaceuticals's current market capitalization is $700.1 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

184.0k295.0k1.2m

Revenue growth, %

60%

General and administrative expense

15.6m19.2m18.3m25.9m

R&D expense

29.5m44.0m41.7m37.0m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

184.0k184.0k184.0k162.0k133.0k252.0k474.0k

General and administrative expense

2.8m4.4m3.7m5.4m4.5m4.9m4.5m4.7m4.3m5.5m6.3m6.7m7.5m4.8m

R&D expense

5.3m6.8m7.5m8.7m11.9m12.1m11.3m11.0m10.1m8.9m9.3m9.0m9.9m10.3m

Operating expense total

8.1m11.2m11.2m14.1m16.4m17.0m15.7m15.7m14.4m14.4m15.6m15.7m17.4m37.3m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

26.1m56.1m20.9m68.8m

Accounts Receivable

254.7m805.4k

Inventories

1.2m1.5m2.0m

Current Assets

97.3m96.1m47.8m118.6m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

133.8m77.7m31.8m22.6m25.9m52.9m27.6m29.2m32.5m22.9m38.8m31.0m43.0m42.4m

Current Assets

134.7m101.3m93.7m89.1m96.7m95.7m81.8m70.7m59.4m36.2m91.7m79.8m101.8m87.6m

PP&E

911.0k1.5m1.9m2.3m2.6m2.7m2.5m2.5m2.4m2.0m1.8m1.7m1.5m

Total Assets

135.9m124.2m116.0m92.7m127.7m113.6m85.5m74.3m62.9m39.4m94.7m82.7m104.1m89.7m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(47.9m)(62.8m)(59.5m)(60.0m)

Depreciation and Amortization

848.0k727.0k840.0k778.0k

Inventories

(44.3m)

Accounts Payable

(97.0k)1.4m1.6m626.0k
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(10.8m)(22.2m)(33.3m)(14.1m)(16.2m)(47.2m)(15.7m)(15.6m)(45.5m)(14.2m)(44.5m)(15.6m)(51.2m)

Depreciation and Amortization

122.0k213.0k419.0k164.0k529.0k207.0k627.0k571.0k195.0k393.0k

Accounts Payable

(621.0k)(272.0k)(119.0k)525.0k1.6m133.0k(227.0k)3.2m983.0k4.1m1.1m(2.9m)(1.2m)

Cash From Operating Activities

(6.4m)(14.3m)(22.4m)(10.6m)(35.5m)(14.3m)(37.2m)(39.4m)(16.5m)(32.3m)
USDY, 2018

Financial Leverage

1.4 x
Show all financial metrics
Report incorrect company information

Dicerna Pharmaceuticals Online and Social Media Presence

Embed Graph
Report incorrect company information

Dicerna Pharmaceuticals News and Updates

Report incorrect company information

Dicerna Pharmaceuticals Blogs

Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 8, 2019-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), (the “Company”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that on January 2, 2019 , the Compensation Committee of the Company's Board of Directors

Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target from Research Collaboration with Dicerna

Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target from Research Collaboration with Dicerna ronryan.teano@… Fri, 01/04/2019 - 07:26 Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target from Research Collaboration with Dicerna Jan 4, 2019…

Dicerna to Join NASDAQ Biotechnology Index

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 20, 2018-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will be added to the NASDAQ Biotechnology Index (Nasdaq:NBI) as part of the

Dicerna Announces Closing of Global Licensing and Research Collaboration with Eli Lilly and Company

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 19, 2018-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the closing of the global licensing and research collaboration between Dicerna and Eli Lilly and

Dicerna to Participate in Citi’s 2018 Global Healthcare Conference

Dicerna to Participate in Citi’s 2018 Global Healthcare Conference Content Import Thu, 11/29/2018 - 07:31 Dicerna to Participate in Citi’s 2018 Global Healthcare Conference Nov 29, 2018 This release is a backfill from a News Wire General …

Dicerna Announces Late-Breaking Data from the PHYOX Phase 1 Clinical Trial of DCR-PHXC Will Be Presented at ASN Kidney Week 2018

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 5, 2018-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that late-breaking data from the PHYOX Phase 1 trial of DCR-PHXC for the treatment of primary
Show more

Dicerna Pharmaceuticals Company Life and Culture

Report incorrect company information

Dicerna Pharmaceuticals Frequently Asked Questions

  • When was Dicerna Pharmaceuticals founded?

    Dicerna Pharmaceuticals was founded in 2007.

  • Who are Dicerna Pharmaceuticals key executives?

    Dicerna Pharmaceuticals's key executives are Douglas M. Fambrough, Bob D. Brown and Jack Green.

  • How many employees does Dicerna Pharmaceuticals have?

    Dicerna Pharmaceuticals has 44 employees.

  • What is Dicerna Pharmaceuticals revenue?

    Latest Dicerna Pharmaceuticals annual revenue is $1.2 m.

  • What is Dicerna Pharmaceuticals revenue per employee?

    Latest Dicerna Pharmaceuticals revenue per employee is $26.9 k.

  • Who are Dicerna Pharmaceuticals competitors?

    Competitors of Dicerna Pharmaceuticals include Urogen Pharma, LAM Therapeutics and Rasna Therapeutics.

  • Where is Dicerna Pharmaceuticals headquarters?

    Dicerna Pharmaceuticals headquarters is located at 87 Cambridge Park Dr, Cambridge.

  • Where are Dicerna Pharmaceuticals offices?

    Dicerna Pharmaceuticals has an office in Cambridge.

  • How many offices does Dicerna Pharmaceuticals have?

    Dicerna Pharmaceuticals has 1 office.